Beta Drugs Ltd Board to Consider Bonus Issue on February 5

Beta Drugs Ltd., a prominent player in the Indian oncology (anti-cancer) pharmaceutical industry, is renowned for manufacturing an extensive array of oncology drugs. With a robust presence both domestically and in export markets, the company ranks among the top 10 oncology firms in India. Many of its flagship products are recognised as market leaders. As of now, Beta Drugs Ltd. boasts a market capitalisation of ₹1,977 crore.

Beta Drugs Ltd., Board Meeting Announcement 

The Board of Directors of Beta Drugs Ltd. will convene on Wednesday, February 5, 2025. During this critical meeting, the Board will deliberate on several key strategic initiatives, including:

1. The proposal for an increase in the authorised share capital of the Company, alongside a consequential amendment to the capital clause in the Memorandum of Association.
2. A discussion on, and approval for, the issuance of Bonus Shares, subject to the approval of the shareholders.
3. The consideration and appointment of distinguished Independent Directors to further strengthen the Board’s expertise.
4. A proposal to migrate the listing and trading of the Company’s equity shares from the Emerge platform of the National Stock Exchange of India (NSE) to the esteemed main board of NSE, in addition to the main board of BSE Ltd.
5. Approval of the draft Notice for the e-voting process through Postal Ballot.
6. Appointment of a Scrutiniser to oversee the Postal Ballot event, ensuring transparency and full compliance with regulatory standards.

Beta Drugs Ltd. Q2 FY25 Financial Results

Beta Drugs Ltd. has announced its financial performance for the first half of the fiscal year 2025, covering the period from 1st April to 30th September 2024. The company reported a revenue of ₹1,803.03 million, reflecting a commendable 28% growth compared to ₹1,412.69 million in the same period last year. 

Net profit surged to ₹244.36 million, an increase of 23% from ₹198.73 million in the previous year. Earnings per share (EPS) reached ₹25.42, marking a solid rise from ₹20.67 in the first half of FY24.

Beta Drugs Ltd. Share Price and Performance 

At 2:29 PM today, Beta Drugs Ltd. shares traded at ₹2,042 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.